NKT2152 demonstrates anti-tumor activity in heavily pretreated advanced clear cell RCC

Immunotherapy in Renal Cell CarcinomaПодробнее

Phase 2 Trial Shows Antitumor Activity in Metastatic Clear Cell RCCПодробнее

Cab + atezo: a new treatment for naïve advanced ccRCCПодробнее

Unmet needs in the treatment of renal cell carcinomaПодробнее

Managing Advanced Renal Cell Carcinoma - QuinnПодробнее

Treatment Landscape of Advanced Clear Cell RCCПодробнее

Understanding and Working With New Immunotherapeutic and Targeted Management Models in Advanced RCCПодробнее

NKT2152, an oral HIF-2α inhibitor, in pre-treated advanced clear cell renal carcinomaПодробнее

RCC MasterClass and Clinical Consult: Novel Immune and Targeted TherapiesПодробнее

Using Combination Therapy as Treatment of Non-Clear Cell RCCПодробнее

Management of locally advanced RCCПодробнее

Immunotherapy-based management of metastatic clear-cell and variant RCC: What can we achieve?Подробнее

First- and second-line treatments for locally advanced renal cell carcinomaПодробнее

First-line ICIs in advanced non-clear cell RCCПодробнее

The combination of sitravatinib and nivolumab for the treatment of advanced clear cell renal cel...Подробнее

Researcher comment: HIF-2α inhibition in RCC | Toni ChouieriПодробнее

Case Presentation: A 69-Year-Old Woman with Advanced RCCПодробнее

KCRS21: Non Clear Cell RCCПодробнее

Kidney Cancer Research: Immunotherapy Combinations in Rare Kidney CancersПодробнее